Sector | Healthcare |
Industry | - |
Day Range | 86.32 | 87.98 |
52-Wk Range | - | - |
Last Close | 86.84 |
Mkt Cap (m) | 16,423.13 |
Dividend yield | 1.43 |
ISIN | BE0003739530 |
Volume | 294,911.00 |
Exchange Venue | BRU |
UCB SA is engaged in the development of novel therapies for the treatment of central nervous system and immunological diseases.
Price/Earning | 22.04 |
Price/Book | 2.32 |
Price/Sales | 3.14 |
P/CF | 18.00 |
Rev Growth (3 year avg) | - |
EPS Growth (3 year avg) | - |
Operating Margin % | - |
Net Margin % | - |
Return on Equity | - |
Debt/Equity | - |
EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
Revenue (m) | 3,876.00 | 4,178.00 | 4,530.00 | 4,632.00 | 4,913.00 | - |
Operating Income (m) | 717.00 | 967.00 | 1,137.00 | 1,163.00 | 1,073.00 | - |
Net Income (m) | 623.00 | 520.00 | 753.00 | 800.00 | 792.00 | - |
Basic EPS | 3.25 | 2.76 | 4.00 | 4.24 | 4.23 | - |
Avg. Diluted Shares Outstanding (m) | 192.08 | 188.37 | 188.28 | 188.48 | 187.22 | - |
EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
Current Assets (m) | 2,838.00 | 2,331.00 | 2,677.00 | 2,950.00 | 3,295.00 | - |
Non Current Assets (m) | 8,118.00 | 7,881.00 | 7,240.00 | 7,564.00 | 7,785.00 | - |
Total Assets (m) | 10,956.00 | 10,212.00 | 9,917.00 | 10,514.00 | 11,081.00 | - |
Current Liabilities (m) | 3,061.00 | 2,418.00 | 1,949.00 | 2,238.00 | 2,394.00 | - |
Total Liabilities (m) | - | - | - | - | - | - |
Total Equity (m) | 5,672.00 | 5,584.00 | 5,813.00 | 6,310.00 | 7,039.00 | - |
EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
Operating Cash Flows (m) | 245.00 | 427.00 | 927.00 | 1,089.00 | 882.00 | - |
Capital Expenditure (m) | -146.00 | -138.00 | -209.00 | -341.00 | -294.00 | - |